The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction

The high activity of Histone deacetylases (HDACs) in hepatocellular carcinoma (HCC) usually positively correlates with poor prognosis of patients. Accordingly histone deacetylases inhibitors (HDACis) are considered to be potential agents treating patients with HCC. In our study, we evaluated effect...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Int J Biol Sci
Main Authors: He, Bin, Dai, Longfei, Zhang, Xiaoqian, Chen, Diyu, Wu, Jingbang, Feng, Xiaode, Zhang, Yanpeng, Xie, Haiyang, Zhou, Lin, Wu, Jian, Zheng, Shusen
פורמט: Artigo
שפה:Inglês
יצא לאור: Ivyspring International Publisher 2018
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6231215/
https://ncbi.nlm.nih.gov/pubmed/30443188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijbs.27661
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים